EMA Grants First Approval for Macitentan Generic, Opening the Market

The European Medicines Agency (EMA) has granted final approval for Macitentan Accord, a generic version of the pulmonary arterial hypertension (PAH) treatment, from Accord Healthcare. This approval marks the beginning of market competition as the patent for Johnson & Johnson's (JNJ) blockbuster drug, Opsumit, is set to expire. Accord Healthcare has successfully navigated the stringent European regulatory process, establishing itself as a first-to-market generic. This will introduce a more affordable alternative to the market for expensive PAH treatments.

Significance of Mechanism of Action and Bioequivalence Verification

Macitentan Accord contains macitentan, an active ingredient classified as a dual endothelin receptor antagonist (ERA). This drug works by blocking the binding of endothelin, a substance that constricts blood vessels, to its receptors, thereby dilating pulmonary blood vessels and lowering blood pressure. European regulatory authorities have confirmed through clinical trials that this generic drug is fully bioequivalent to the original drug, Opsumit. This is significant because it provides patients with access to a safe and effective treatment at a more reasonable cost.

Decline in Market Share of the Original Blockbuster and Market Restructuring

The original drug, Opsumit, recorded global sales of $2.184 billion in 2024, making it a major blockbuster. This generic approval is expected to create a significant challenge to Johnson & Johnson's market defense in Europe. European countries' public healthcare systems have been under considerable pressure due to the high cost of new drugs, and they are actively welcoming the introduction of affordable generics. As a result, the market dominance of Opsumit is likely to be eroded, and physicians' prescribing patterns may shift rapidly towards generics.

Intensified Competition in the PAH Treatment Market and Mid- to Long-Term Prospects

The global PAH treatment market is currently estimated at $8.4 billion to $9.1 billion in 2025 and 2026. With more generic competitors expected to enter the market, Accord Healthcare will need to focus on quickly securing its initial market supply chain. In addition, the entry of innovative new drugs such as sotatercept is expected to intensify competition among existing ERA drugs, and Accord Healthcare's ability to establish a robust distribution network and reliably supply the drug will be key to its future commercial success.